Company / FCF Margin
ENANTA PHARMACEUTICALS INC FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-141.7%
FY2025
5-year range
-141.7% / 32.2%
FY2021-FY2025
Trend
-40.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has declined for 4 consecutive years, from 32.2% in FY2021 to -141.7% in FY2025.
Based on SEC 10-K filings.
-141.7% in FY2025 with a 5-year CAGR of -154.4%.
Declined from -72.9% to -141.7% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -146.3pp
- 5-Year Change
- -154.4pp
- 10-Year Change
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's fcf margin has declined for 4 consecutive years.
- In FY2025, fcf margin decreased 40.4% year-over-year.
- Peak fcf margin was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -141.7% | -40.4% |
| FY2024 | -100.9% | -38.4% |
| FY2023 | -72.9% | -1680.9% |
| FY2022 | 4.6% | -85.7% |
| FY2021 | 32.2% | +153.2% |
| FY2020 | 12.7% | -74.0% |
| FY2019 | 48.8% | +38.6% |
| FY2018 | 35.2% | -23.8% |
| FY2017 | 46.2% | +15.2% |
| FY2016 | 40.1% | +28.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026